



Press Release

Truffle Capital announces the close of Symetis acquisition for \$435 million by Boston Scientific

Paris, May 17th, 2017 – Truffle Capital, a leading European venture capital firm aimed at creating young innovative companies and supporting their development, announces today the close of Symetis acquisition, leader in the field of percutaneous heart valve replacement solutions (TAVI), by Boston Scientific (<http://news.bostonscientific.com/2017-05-16-Boston-Scientific-Closes-Symetis-Acquisition>) for \$435 million¹.

Truffle Capital has been an historical investor of Symetis since its creation and has been involved in all its development stages: R&D, clinical development, industrialization, CE-marking and marketing in Europe (€35 million in sales in 2016).

Truffle Capital is also co-founder and investor of Carmat (artificial heart), Epygon (mitral valve), Kephalius (adjustable mitral annuloplasty device) and Kardiosis (endoprosthesis for aortic aneurysm) in the field of cardiovascular devices; of Vexim (SpineJack® implant for vertebral fractures) in orthopedics; of Myopowers (artificial sphincter) in urology and of Théraclion (Echotherapy for tumors).

About Truffle Capital

Truffle Capital is an independent European venture capital firm founded in 2001 by its co-founders Henri Moulard, Philippe Pouletty MD. and Bernard-Louis Roques. Truffle Capital is chaired by Patrick Kron alongside its co-founders and Managing Directors, Philippe Pouletty and Bernard-Louis Roques.

Truffle Capital's assets, as of December 31st, 2015, totaled € 730 million under management, mostly via institutional and retail private equity funds (FCPRs and FCPIs). Truffle Capital specializes in investments in companies developing breakthrough technologies and products in the Information Technology and Life Sciences sectors, in spin-offs and new ventures. For more information, please visit www.truffle.fr

Press contacts:

Alize RP

Caroline Carmagnol and Wendy Rigal

truffle@alizerp.com

+33 (0) 1 44 54 36 62 / + 33 (0) 6 64 18 99 59

¹ Press release issued by Symetis on March 30th, 2017:

https://www.symetis.com/sites/default/files/symetis_and_boston_scientific_reach_usd_435_million_purchase_agreement.pdf